ERNA vs OLB Comparison

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

The OLB Group Inc is a diversified FinTech company that focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. The company seeks to provide merchants with a wide range-of-products and services through the various online platforms, including financial and transaction processing services. It also has products that provide support for crowdfunding and other capital-raising initiatives. It supplements the online platforms with certain hardware solutions that are integrated with the online platforms. The company has two business segments: Fintech Services, which generates key revenue, and the Bitcoin Mining business segment.